Protagonist Therapeutics (PTGX) Long-Term Investments (2016 - 2026)

Protagonist Therapeutics has reported Long-Term Investments for 9 years, with the latest figure at $72.5 million in Q1 2026.

• Quarterly Long-Term Investments fell 41.26% year-over-year to $72.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.5 million (down 41.26% YoY) and the FY2025 annual result came in at $78.6 million, down 43.98% from the prior year.
• Long-Term Investments declined to $72.5 million in Q1 2026 per PTGX's latest filing, from $78.6 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $140.3 million in Q4 2024 and troughed at $2.0 million in Q3 2023.
• A 4-year average of $85.4 million and a median of $102.5 million in 2025 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2024 and 2025: Long-Term Investments jumped 5673.3% in 2024, then plunged 43.98% in 2025.
• Over 4 years, Long-Term Investments stood at $2.0 million in 2023, then soared by 6968.01% to $140.3 million in 2024, then slumped by 43.98% to $78.6 million in 2025, then retreated by 7.7% to $72.5 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $72.5 million, $78.6 million, and $102.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.